Adenocarcinoma of the pancreas is the fourth most common cause of cancer death in the United States. It affects about 28,600 Americans each year and the mortality rate equals the incidence. Five to 10 percent of cases aggregate in families generally in a pattern consistent with autosomal dominant transmission with variable penetrance. There are a few rare syndromes for which a genetic etiology has been identified. However, the etiology has not been defined for the majority of familial cases. Identification of high-risk families and registration of the members is fundamental as a resource for gene discovery and future studies to refine identification of environmental factors, develop prevention strategies and test interventions.
The aim of this proposal is to develop a high-risk population registry to provide a basis for future research and the specific objectives are: 1) Characterize the families with clustering of pancreatic cancer identified in the Utah Population Database (UPDB), 2) Create a registry of these families, 3) Procure blood and tissue blocks for DNA extraction, 4) Establish systems necessary so that the persons in this registry are available to participate in future studies to include gene discovery, identification and validation of environmental and lifestyle risk factors, chemoprevention trials, and interventional studies that potentially could include medical (targeted gene therapy, tumor vaccines), surgical and endoscopic modalities. The investigators intend to participate in an international consortium of registries currently in development to increase the statistical power for such studies as listed above. Established and validated genetic epidemiological techniques developed at this institution will be used to characterize the families. Probands, or next of kin for deceased persons, from informative families will be contacted and invited to participate using a validated method that assures confidentiality. For consenting families, a family advocate will be identified to recruit relatives and assist in refining the pedigree. Consent will be obtained to collect medical records and pancreatic cancer tissue blocks from the proband. The pedigrees will be expanded and registered. Subjects will be notified of future registry studies to include questionnaire completion, blood testing for DNA, and clinical trials to be developed. This proposal will allow the investigators to provide access a unique and important resource on a local and a national level. The goal corresponds with the National Cancer Institute Initiative to """"""""identify, characterize, and understand the genes that cause or play a role in familial cancer.""""""""

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Research Grants (R03)
Project #
5R03CA096429-02
Application #
6627747
Study Section
Special Emphasis Panel (ZCA1-SRRB-Q (J1))
Program Officer
Seminara, Daniela
Project Start
2002-06-01
Project End
2005-05-31
Budget Start
2003-06-01
Budget End
2005-05-31
Support Year
2
Fiscal Year
2003
Total Cost
$75,000
Indirect Cost
Name
University of Utah
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
009095365
City
Salt Lake City
State
UT
Country
United States
Zip Code
84112
Kuptsova, Nataliya; Kopecky, Kenneth J; Godwin, John et al. (2007) Polymorphisms in DNA repair genes and therapeutic outcomes of AML patients from SWOG clinical trials. Blood 109:3936-44
Sarosdy, Michael F; Tangen, Catherine M; Weiss, Geoffrey R et al. (2005) A phase II clinical trial of oral bropirimine in combination with intravesical bacillus Calmette-Guerin for carcinoma in situ of the bladder: a Southwest Oncology Group Study. Urol Oncol 23:386-9
Stiff, Patrick J; Shpall, Elizabeth J; Liu, P Y et al. (2004) Randomized Phase II trial of two high-dose chemotherapy regimens with stem cell transplantation for the treatment of advanced ovarian cancer in first remission or chemosensitive relapse: a Southwest Oncology Group study. Gynecol Oncol 94:98-106
Rothenberg, Mace L; Liu, P Y; Wilczynski, Sharon et al. (2004) Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study. Gynecol Oncol 95:506-12
Parker, Jana Foley; Florell, Scott R; Alexander, April et al. (2003) Pancreatic carcinoma surveillance in patients with familial melanoma. Arch Dermatol 139:1019-25
Rothenberg, Mace L; Liu, P Y; Braly, Patricia S et al. (2003) Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial. J Clin Oncol 21:1313-9
Blayney, Douglas W; LeBlanc, Michael L; Grogan, Thomas et al. (2003) Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349). J Clin Oncol 21:2466-73
Velasquez, William S; Lew, Danika; Grogan, Thomas M et al. (2003) Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501. J Clin Oncol 21:1996-2003
Hawes, Debra; Liu, P Y; Muggia, Franco M et al. (2002) Correlation of p53 immunostaining in primary and residual ovarian cancer at the time of positive second-look laparotomy and its prognostic role: a Southwest Oncology Group ancillary study. Gynecol Oncol 87:17-23
Sosman, Jeffrey A; Unger, Joseph M; Liu, P-Y et al. (2002) Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J Clin Oncol 20:2067-75

Showing the most recent 10 out of 26 publications